drugset
drugset / Trial / NCT01093677

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance

NCT01093677 ↗

Phase 1 Withdrawn 30 enrolled Limerick BioPharma
RandomizedParallel-groupSingle-blindTreatment

Summary

LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance

Timeline

Start
2010-03
Primary completion
2010-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject QUERCETIN-3'-O-PHOSPHATE Small molecule 750 mg Oral

Indications

glucose intolerance